杂志简称：cancer biother radio
中文译名：《癌症生物治疗与放射性药物》
收录属性：scie（2024版）, 目次收录（维普）, 目次收录（知网）,英文期刊,
自引率：3.20%
投稿方向：医学、medicine, research & experimental医学、研究与实验、oncology肿瘤学、pharmacology & pharmacy药学、radiology, nuclear medicine & medical imaging核医学
SCI/E期刊基本信息
出版周期：年10期 地区：美国
中科院分区：4区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN 1084-9785；EISSN 1557-8852
杂志语言：英语
出版国家：美国
杂志官网 联系方式
出版地址：140 HUGUENOT STREET,3RD FL,NEW ROCHELLE,USA,NY,10801
杂志邮箱：
投稿网址：https://mc.manuscriptcentral.com/cancerbiotherapy
杂志官方网址：https://home.liebertpub.com/publications/cancer-biotherapy-and-radiopharmaceuticals/8/
出版商网址：http://www.liebertpub.com/
杂志投稿要求
投稿须知【杂志社官方网站信息】
Cancer Biotherapy and Radiopharmaceuticals
For Authors
Manuscript Submission Guidelines
View General Guidelines
Journal Information
Manuscript Submission Site: https://mc.manuscriptcentral.com/cancerbiotherapy
Editorial Office Contact: kcloudhansen@liebertpub.com
Support Contact: prosupport@liebertpub.com
Journal Model: Hybrid (Open Acess Option)
Blinding: Single Blind
File formatting requirement stage: Upon submission
Instant Online Option (immediate publication of accepted version): No
Submission Fee: $50.00. Click here to purchase your submission token.
Average time to initial decision: 18 days
About the Journal
Cancer Biotherapy and Radiopharmaceuticals invites original contributions on all research related to furthering the study of cancer therapeutics and research at the intersection of that therapy with radiopharmaceuticals for both diagnostic and therapeutic applications. The mission of the journal is to communicate advances in fields including biotherapy, targeted drug and radionuclide delivery, nanotechnology, and studies that advance the understanding of the mechanism of action and response of cancer to therapeutics. It is the expectation of this journal that all of the biological, chemical, and radiochemical tools be rigorously applied, characterized appropriately with the results of the studies in submitted manuscripts supported by the application of both rigorous controls and wherever appropriate, statistics. If you are uncertain if your work falls within the scope of the journal, please email the title and abstract of the paper to the editorial office prior to submission.
Manuscript Types and Guidelines
Original Articles
Comprehensive complete accounts of significant studies should be submitted as Original Articles (the majority of submissions fall under this category).
3,000-word limit
Structured abstract of no more than 200 words
Maximum total of ten (10) figures and/or tables
Maximum of 100 references
Uncropped western blots must be uploaded as supplemental data.
Review Articles
Suitable review articles that fall within the purview of the journal may introduce readers to topics of current interest or provide comprehensive updates to specific fields and topics that fall within the purview of the journal. Reviews should provide a concise overview of fundamental topics and translational issues. Reviews should be accessible to the broad readership of Cancer Biotherapy and Radiopharmaceuticals.
5,000-word limit
Abstract of no more than 250 words
Maximum total of ten (10) figures and/or tables
Maximum of 150 references
Uncropped western blots must be uploaded as supplemental data.
Short Reports
Technical Notes or Short Reports are a third category that is intended to provide publication of brief transformative techniques and methodology that researchers will potentially find of value and use in their respective laboratories. These are, by their nature, intended to be brief and concise (2-3 journal pages), yet fully informative to facilitate immediate use of the related information.
1,200-word limit
Abstract of no more than 100 words
Maximum total of five (5) figures and/or tables
Maximum of 10 references
Uncropped western blots must be uploaded as supplemental data.